Clinical Trials Logo

Clinical Trial Summary

A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects


Clinical Trial Description

A Phase 1 Randomized, Single Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05178901
Study type Interventional
Source Public Health Vaccines LLC
Contact
Status Completed
Phase Phase 1
Start date January 10, 2022
Completion date May 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05398796 - Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults Phase 1
Recruiting NCT06221813 - Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects Phase 1
Completed NCT04199169 - Safety and Immunogenicity of a Nipah Virus Vaccine Phase 1